Pneumonia therapeutics are vital for management and complete recovery from the disease. Pneumonia is a bacterial or viral infection that disrupts the normal functioning of lungs. This inflammatory condition affects the alveoli or small air sacs of lungs. Fever, dry cough, difficult breathing, and chest pain are the common symptoms of this disease. Pneumonia becomes more critical for those with weak immune systems, especially new-borns and elderly.
Modes of Treatment
Being an inflammatory condition of lungs, pneumonia patients require antibiotics, fluids, proper rest, and medical care. Patients are prescribed with oxygen supplementation to ensure proper breathing for those with breathing difficulties. Thera are two ways to manage the oxygen supplementation, namely, nasal cannula and mechanical ventilation. The latter makes use of life support system called ventilator. Ventilation can be mechanically provided in both invasive and non-invasive ways.
Invasive mechanical ventilation enables life support to the patient through a tube. This tube is inserted into the windpipe either through nose, mouth or a hole created in the windpipe at the front side of the throat. On the other hand, non-invasive mechanical ventilation facilitates can provide ventilator support by means of tight nasal or facial mask.
Preventive Measures
In June 2017, a pneumococcal vaccine “Synflorix’’, developed by GlaxoSmithKline plc received a positive feedback from the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA). Dosage of this drug is prescribed to consume for improved immunity against Pneumonia. It can treat invasive diseases and acute otitis media caused by streptococcus pneumoniae especially in infants and children up to five years of age.
Market Overview
According to Grand View Research, Inc.; the global pneumonia therapeutics market may achieve around USD 22.9 billion by 2025. Rising research and development activities in life sciences are expected to positively impact the market in the near future. Government initiatives for prevention and treatment of pneumonia are anticipated to further boost the market.
Vaccines acquired the largest market share in 2016. Rising consciousness among populace regarding prevention and care is the major driving factor. Drugs and oxygen on the other hand, may show considerable growth over the forecast period (2014 to 2025). Asia Pacific is may exhibit momentous growth in forthcoming years due to high prevalence of pneumonia.
Key participants operating in the global market are GlaxoSmithKline plc; Pfizer, Inc.; Abbott; Allergan; and Merck & Co, Inc.
In-Depth research report on Pneumonia Therapeutics Market:
https://www.grandviewresearch.com/industry-analysis/pneumonia-market
No comments:
Post a Comment